Evidence map›Paper›PMID 28069036›Full record

ArticleWorld journal of surgical oncology2017

TPX2 expression is associated with poor survival in gastric cancer.

Chiharu Tomii, Mikito Inokuchi, Yoko Takagi, Toshiaki Ishikawa, Sho Otsuki, Hiroyuki Uetake, Kazuyuki Kojima, Tatsuyuki Kawano

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. MiR-711 regulates gastric cancer progression by targeting CD44.Cancer biomarkers : section A of Disease markers · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chiharu TomiiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Mikito InokuchiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. m-inokuchi.srg2@tmd.ac.jp.
Yoko TakagiDepartment of Surgical Specialties, Tokyo Medical and Dental University, Tokyo, Japan.
Toshiaki IshikawaDepartment of Surgical Specialties, Tokyo Medical and Dental University, Tokyo, Japan.
Sho OtsukiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Hiroyuki UetakeDepartment of Surgical Specialties, Tokyo Medical and Dental University, Tokyo, Japan.
Kazuyuki KojimaDepartment of Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Tatsuyuki KawanoDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Tokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein required for microtubule formation in human cells. Several studies have demonstrated that TPX2 is overexpressed in multiple tumor types and promotes tumor growth and metastasis. However, there have been few reports regarding its role in gastric cancer. In this study, we evaluated TPX2 expression and investigated its correlations with gastric cancer clinicopathological features and prognosis.

methodsTumor samples were obtained from 290 patients with gastric adenocarcinoma who had undergone gastrectomy. The expression of TPX2 protein was examined using immunohistochemical staining. TPX2 messenger RNA (mRNA) levels were evaluated using real-time quantitative reverse transcription PCR in 19 of the gastric cancer tumors and adjacent normal tissues.

resultsThe mRNA levels of TPX2 were significantly higher in gastric cancer tissues than in matched adjacent normal tissues (p = 0.004). In the immunohistochemical analysis, TPX2 overexpression was found in 123 (42.4%) of 290 patients. High TPX2 expression was positively associated with age, type of histology, depth of tumor, lymph node metastasis, stage, and remote metastasis or recurrence. High TPX2 expression was significantly associated with poorer disease-specific survival (p = 0.004) and relapse-free interval (p = 0.013).

conclusionsOur results indicated that high TPX2 expression was associated with tumor progression and poor survival in gastric cancer.

Indexed as

AdenocarcinomaAgedBiomarkers, TumorCase-Control StudiesCell Cycle ProteinsFemaleFollow-Up StudiesGastrectomyGastric MucosaHumansImmunoenzyme TechniquesLymphatic MetastasisMaleMicrotubule-Associated ProteinsNeoplasm InvasivenessNeoplasm Recurrence, LocalBiomarkers, TumorCell Cycle ProteinsMicrotubule-Associated ProteinsNuclear ProteinsRNA, MessengerTPX2 protein, humanGastric cancerImmunohistochemistryPrognostic markerTPX2

Identifiers

PMID28069036
PMCPMC5223319
OpenAlexW2570025250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.